Expertise in
3
conditions

Daniel Morillo

Madrid, MD, ES 
Expertise in
3
conditions
Madrid, MD, ES 

Overview

Daniel Morillo practices practicing medicine in Madrid, Spain.

Mr. Morillo is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, Anemia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Madrid, MD, Spain
Other Locations
Majadahonda, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: HPN217
Study Phase: Phase 1
Effectiveness and Safety for Re-treatment With Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) CD30+ Malignancies: a Retrospective Medical Chart Review Study in Spain
Effectiveness and Safety for Re-treatment With Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) CD30+ Malignancies: a Retrospective Medical Chart Review Study in Spain
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Other
View 1 Less Clinical Trial

43 Total Publications

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: August 30, 2026

Frequently Asked Questions about Daniel Morillo

Is Daniel Morillo a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Daniel Morillo is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Daniel Morillo participate in research or clinical trials?

Yes. Daniel Morillo has published 43 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Daniel Morillo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Morillo's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile